A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 487 participants.

Also called NCT06952530

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 487 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06952530
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, China, Czechia, Germany, Greece, India, Japan, Poland, Puerto Rico, Spain (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06952530. Randomized; double masking; primary purpose treatment. Start 2025-04-30 (actual); primary completion 2027-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
Condition
Hypertension
Intervention (Drug)
Orforglipron
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct06952530
Content hash
a0fecfcbc50ec04d0589be4bb96ad88728e0f56f04d6308f242411ff150fd83c